Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Above 50 Day Moving Average – Here’s What Happened

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$14.60 and traded as high as C$14.82. Cipher Pharmaceuticals shares last traded at C$14.74, with a volume of 6,877 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus dropped their target price on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday, November 11th. Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Cipher Pharmaceuticals Stock Down 3.1 %

The firm has a market cap of C$365.43 million, a PE ratio of 11.42 and a beta of 1.20. The company’s 50 day moving average price is C$14.59 and its two-hundred day moving average price is C$14.03. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 EPS for the quarter, missing the consensus estimate of C$0.03 by C($0.02). The firm had revenue of C$14.15 million for the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. On average, equities research analysts expect that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.